
Amneal Pharmaceuticals, Inc.
Publicly traded US pharmaceutical company founded 2002, maker of generic, specialty, and biosimilar medicines including UNITHROID, CREXONT, and a broad affordable medicines portfolio.
Company Type
public
Founded
2002
Headquarters
Bridgewater, New Jersey, USA
Stock
Nasdaq: AMRX
Revenue
Approximately $3.0 billion (FY2025); guidance of $3.15 to $3.25 billion (FY2026)
Employees
Approximately 7,700
Primary Market
United States
Amneal Pharmaceuticals, Inc. Timeline
Shop Amneal Pharmaceuticals, Inc. Brands
Disclosure: We may earn commission from purchasesAbout Amneal Pharmaceuticals, Inc.
Is Amneal Pharmaceuticals publicly traded?
Yes. Amneal Pharmaceuticals, Inc. trades on the Nasdaq under the ticker AMRX. The company went public in May 2018 through its merger with Impax Laboratories.
Who founded Amneal?
Brothers Chirag Patel and Chintu Patel founded Amneal in 2002 in New Jersey. Both men, who are pharmacists by training, continue to serve as co-chief executives of the company.
What does Amneal make?
Amneal manufactures more than 250 pharmaceutical products across generics, injectables, transdermal patches, biosimilars, and branded specialty medicines. Its branded products include CREXONT, BREKIYA, RYTARY, and UNITHROID.
What is Amneal's revenue?
Amneal generated approximately $3.0 billion in net revenue in fiscal 2025 and guided to $3.15 to $3.25 billion for fiscal 2026. Third quarter 2026 revenue was $863 million, up 10 percent year over year.
Does Amneal own UNITHROID?
Amneal distributes UNITHROID through its Amneal Specialty division under a 10-year license and supply agreement signed in 2018 with Jerome Stevens Pharmaceuticals, which continues to manufacture the product in Bohemia, New York.
Where are Amneal's factories?
Amneal operates manufacturing and development sites in New Jersey and New York in the United States, plus facilities in India and Ireland. Its workforce of approximately 7,700 spans 11 countries.
History of Amneal Pharmaceuticals, Inc.
Amneal was founded in 2002 by Chirag and Chintu Patel, pharmacist brothers who had immigrated from India and worked in the US generics industry. The company began with a small portfolio of generic products and a strategy of pursuing formulations other manufacturers found difficult to produce.
Through the 2000s, Amneal grew by winning Abbreviated New Drug Application approvals from the FDA and by acquiring small product portfolios. Its early identity was built on controlled substances and technically demanding generics, segments with fewer competitors than commodity oral solids.
In 2012, Amneal took a first major step toward scale by acquiring the US generics business of Watson-adjacent assets, and in subsequent years it added manufacturing sites in New York and New Jersey. By the mid-2010s it had become one of the fastest-growing private generics companies in the country.
The decisive transaction came in 2018. Amneal merged with Impax Laboratories, a Nasdaq-listed generics maker, in a deal that created Amneal Pharmaceuticals, Inc. as a public company in May 2018. The merger gave Amneal a Nasdaq listing under ticker AMRX, a larger generics portfolio, and Impax's specialty business, which included the Parkinson's drug RYTARY, the foundation of the current Specialty segment.
In 2019, Amneal acquired a majority stake in AvKARE, a Tennessee-based distributor serving government and institutional buyers, adding a third reporting segment. The same year it signed a 10-year license and supply agreement with Jerome Stevens Pharmaceuticals for levothyroxine, bringing the UNITHROID brand under Amneal Specialty distribution.
The early 2020s brought heavy investment in higher-value categories: complex injectables, transdermal systems, biosimilars, and women's health patches. Amneal launched CREXONT, an extended-release carbidopa-levodopa formulation for Parkinson's disease, in 2024, and added the BREKIYA autoinjector for migraine.
In 2025, Amneal acquired Kashiv BioSciences, a New Jersey biosimilars and complex injectables developer, in a transaction valued at approximately $1 billion including milestones. The deal gave Amneal a biosimilars pipeline and commercial-stage products, and integration continued through 2026.
Through 2026, the company's results accelerated. Third quarter net revenue reached $863 million, up 10 percent year over year, with Affordable Medicines up 19 percent and Specialty up 20 percent on strength from CREXONT, BREKIYA, and UNITHROID. Management raised full-year guidance several times during the year.
Amneal Pharmaceuticals, Inc. Sustainability & Ethics
Amneal publishes an annual corporate sustainability report covering environmental, social, and governance metrics. Its commitments include greenhouse gas tracking across manufacturing sites, pharmaceutical waste management, and supplier conduct standards.
The company's access-to-medicines positioning is central to its ethics narrative. As a generics manufacturer, its core business model is selling lower-cost alternatives to branded drugs, which management frames as expanding access to affordable treatment. The company reports donations of medicines through relief organizations and participation in government supply programs through AvKARE.
On governance, the dual-role structure of founders as co-CEOs and significant LLC interest holders has drawn occasional commentary from governance analysts, though no formal action has been taken. The company maintains standard FDA compliance programs across its manufacturing network and has received warning letters at individual facilities in past years, subsequently resolved.
Awards & Recognition
- Generic Pharmaceutical Association (now AAM) recognition: Amneal has received industry recognition for manufacturing excellence and product launches across multiple years.
- New Jersey business rankings: The company has appeared on lists of the state's largest and fastest-growing public companies.
Controversy, Regulation & Public Scrutiny
Amneal's most significant legal exposure has come from the industrywide generic drug price-fixing litigation brought by US states and private purchasers. Amneal agreed to a settlement of approximately $92.5 million in 2024 to resolve certain antitrust claims, one of several settlements by generic manufacturers in the multidistrict litigation. The company denied wrongdoing as part of the settlement.
Like other opioid-era generic manufacturers, Amneal has been named in opioid-related litigation by municipalities and states alleging contributions to the opioid crisis through distribution of generic opioid products. These matters have been addressed through national settlement frameworks involving the broader generic industry.
The company has also received FDA observations and warning letters at individual manufacturing sites over the years, a routine feature of the generics business. Inspectional findings have been addressed through corrective action plans without major product disruptions.
Brands Owned by Amneal Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. owns 1 brand in our database. Explore the ownership tree below — click categories to expand and see individual brands.
Amneal Pharmaceuticals, Inc.
public · Founded 2002 · Bridgewater, New Jersey, USA
1
brands
Stock Information
Amneal Pharmaceuticals, Inc. Ownership: Pros & Cons
Advantages
- +Founder-led management with two decades of operating continuity and significant insider ownership
- +Three-segment structure balancing generics volume, specialty margins, and distribution income
- +Biosimilars pipeline from the 2025 Kashiv acquisition positioned in a growing category
- +Raised FY2026 guidance multiple times with adjusted EBITDA up 30 percent in Q3
- +Complex product focus reduces exposure to commodity generic price erosion
Considerations
- -Acquisition-driven growth carries integration risk, including the $1 billion Kashiv deal
- -GAAP net loss in Q3 2026 driven by acquisition and integration costs
- -Debt load accumulated through successive transactions
- -Generic price-fixing settlement and opioid litigation reflect industry legal exposure
- -Concentrated US revenue leaves the company sensitive to domestic pricing policy
Frequently Asked Questions About Amneal Pharmaceuticals, Inc.
Is Amneal Pharmaceuticals publicly traded?
Yes. Amneal Pharmaceuticals, Inc. trades on the Nasdaq under the ticker AMRX. The company went public in May 2018 through its merger with Impax Laboratories.
Who founded Amneal?
Brothers Chirag Patel and Chintu Patel founded Amneal in 2002 in New Jersey. Both men, who are pharmacists by training, continue to serve as co-chief executives of the company.
What does Amneal make?
Amneal manufactures more than 250 pharmaceutical products across generics, injectables, transdermal patches, biosimilars, and branded specialty medicines. Its branded products include CREXONT, BREKIYA, RYTARY, and UNITHROID.
What is Amneal's revenue?
Amneal generated approximately $3.0 billion in net revenue in fiscal 2025 and guided to $3.15 to $3.25 billion for fiscal 2026. Third quarter 2026 revenue was $863 million, up 10 percent year over year.
Does Amneal own UNITHROID?
Amneal distributes UNITHROID through its Amneal Specialty division under a 10-year license and supply agreement signed in 2018 with Jerome Stevens Pharmaceuticals, which continues to manufacture the product in Bohemia, New York.
Where are Amneal's factories?
Amneal operates manufacturing and development sites in New Jersey and New York in the United States, plus facilities in India and Ireland. Its workforce of approximately 7,700 spans 11 countries.








